ARTICLE | Distillery Therapeutics
A pyrrolopyrimidine-based TYRO3 inhibitor for primary effusion lymphoma
August 1, 2019 4:38 AM UTC
INDICATION: Non-Hodgkin lymphoma (NHL)...
BCIQ Company Profiles
BCIQ Target Profiles
INDICATION: Non-Hodgkin lymphoma (NHL)...
BCIQ Company Profiles
BCIQ Target Profiles
BCIQ Company Profiles
BCIQ Target Profiles